Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00462228 · ClinicalTrials.gov registry record · Phase 4
Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury
A Phase 4 study, sponsored by University of Missouri-Columbia.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT00462228 is a Phase 4 study that was terminated before completion, run by University of Missouri-Columbia. The registered enrollment target is 11 participants.
The verdict
NCT00462228, a Phase 4 study, was terminated before completion, sponsored by University of Missouri-Columbia.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether memantine (Namenda) improves memory and attention in patients with mild to moderate traumatic brain injury.
Interventions
- DRUG Placebo
- DRUG Memantine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2007-04 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00462228
The ClinicalTrials.gov registry entry for NCT00462228 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Missouri-Columbia, which has 291 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00462228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00462228 about?
NCT00462228 is a clinical study titled "Effect of Namenda on Short Term Memory and Attention in Patients With Mild to Moderate Traumatic Brain Injury". The purpose of this study is to determine whether memantine (Namenda) improves memory and attention in patients with mild to moderate traumatic brain injury.
What is the current status of trial NCT00462228?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2007-04. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00462228?
The interventions under investigation include: Placebo (DRUG), Memantine (DRUG).
Who is sponsoring clinical trial NCT00462228?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.